The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trialPeter Dubsky, Martin Filipits, Edgar Petru et al.|European Journal of Cancer|2020Cited by 52
Pembrolizumab + GVD with ctdna-guided consolidation for relapsed/refractory classic Hodgkin lymphoma: A multicenter phase 2 Study of the University of California hematologic malignancies consortiumMichael P. Randall, Michael A. Spinner, Wendy Swetzig Dhiman et al.|Blood|2025Cited by 1